【正文快照】： 原发性抗中性粒细胞胞浆抗体(ANCA)相关性血管炎(AASV)是一组以血管壁炎症和坏死为主要病理表现的免疫系统疾病,常累及多个脏器,肺脏是最易受累的脏器之一,部分患者以呼吸系统受累为首发...
基于21个网页-相关网页
相关性小血管炎 AASV ; ANCA associated systemic Vasculitis
相关系统性血管炎 AASV
相关性系统性小血管炎 AASV ; ANCA associated systemic vasculitis
相关性系统性血管炎 ANCA-associated systemic vasculitis
移植物和患者的生存率与ANCA相关性血管炎的患者相比，那些在非糖尿病患者中观察到。
Graft and patient survival rates among patients with ANCA-associated vasculitis are comparable to those observed in nondiabetic patients.
用利妥昔单抗治疗难治性ANCA相关性血管炎时，其缓解率可达80%到90%，可能比环磷酰胺疗法更安全。
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.
ANCA相关性血管炎患者的死亡率不断提高，我们的能力，以应对在这个患者人群肾功能衰竭的后果变得极为重要。
As the mortality of patients with ANCA-associated vasculitis continues to improve, our ability to address the consequences of renal failure in this patient population becomes Paramount.
应用推荐